SurgiVision IPO seeks to raise $30 million: Magnetic resonance image-guided surgery system developer plans an initial public offering of up to $30 million of common stock to support further R&D. SurgiVision's technology "enables physicians to see inside the brain and heart using direct, intra-procedural [MRI] guidance while performing minimally invasive procedures," the company explains in a preliminary IPO prospectus recently filed with the Securities and Exchange Commission. Farthest along in the product pipeline is SurgiVison's ClearPoint neurological intervention system, designed for "linear, point-to-point, minimally invasive procedures performed in a standard 1.5T MRI suite," SurgiVision states. A 510(k) application for the device is currently pending at FDA. Also under development is the firm's ClearTrace cardiac intervention system for non-linear, catheter-based surgical procedures using a 3T MRI scanner; SurgiVision is collaborating with MRI scanner manufacturer Siemens on that project. Headquartered in Memphis, Tenn., SurgiVision is also working with Boston Scientific under its SafeLead program to incorporate MRI-safety technologies into the latter firm's implantable cardiac rhythm management and neuromodulation leads. Rodman & Renshaw is underwriter for the proposed IPO
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.
BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.
The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel
